[Effect of terginan on treatment of patients with inflammatory processes in the cervix uteri].
Expediency was studied of use of the drug terginan in a combined treatment of uterine neck pathologies in patients presenting with local inflammatory processes. The drug was found to be capable of dispelling an unspecific inflammatory process, normalizing the vaginal microbe landscape, promoting the postcryodestruction epithelization processes as evidenced by the analysis of the results obtained.
Sukhanova
A A
AA
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D009355:Neomycin / Q000627:therapeutic use; D009761:Nystatin / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D002577:Uterine Cervical Diseases / Q000188:drug therapy* / Q000382:microbiology / Q000601:surgery
D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D009761:Nystatin; D011239:Prednisolone; D009355:Neomycin